{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-078839","form_type":"8-K","ticker":null,"cik":"0000786947","company_name":"ACURA PHARMACEUTICALS, INC","filed_at":"2026-06-29T20:16:08+00:00","discovered_at":"2026-06-29T20:17:00.308860+00:00","generated_at":"2026-06-29T20:17:51.938204+00:00","sec_items":["1.01","2.01","2.03","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Acura extends loan maturity and NDA deadline with AD Pharma, warns of possible shutdown","bullets":["Received $200,000 loan from AD Pharma on June 24, 2026, bringing principal balance to $10,694,279 with accrued interest of ~$1.16M.","Extended NDA acceptance deadline for LTX-03 from June 30, 2026 to December 31, 2026 via amendment #14 to license agreement.","Extended maturity date of secured promissory note from June 30, 2026 to December 31, 2026 via amendment #8.","Extended warrant expiration date to December 31, 2026 and noted AD Pharma owns ~65% of outstanding common stock.","Warns that without additional financing by late July 2026, may need to scale back operations, furlough employees, or seek bankruptcy protection."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-078839","json":"https://secwatch.observer/filing/0001104659-26-078839.json","markdown":"https://secwatch.observer/filing/0001104659-26-078839.md","text":"https://secwatch.observer/filing/0001104659-26-078839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/786947/000110465926078839/0001104659-26-078839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/786947/000110465926078839/tm2619325d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T20:17:51.938204+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}